Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $12.6 million.

  • Altimmune's Total Current Liabilities rose 4593.66% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 4593.66%. This contributed to the annual value of $10.5 million for FY2024, which is 1379.4% down from last year.
  • Latest data reveals that Altimmune reported Total Current Liabilities of $12.6 million as of Q3 2025, which was up 4593.66% from $9.2 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Total Current Liabilities registered a high of $19.1 million during Q3 2021, and its lowest value of $8.6 million during Q3 2024.
  • In the last 5 years, Altimmune's Total Current Liabilities had a median value of $12.1 million in 2023 and averaged $13.1 million.
  • In the last 5 years, Altimmune's Total Current Liabilities surged by 20390.61% in 2021 and then crashed by 3916.2% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Total Current Liabilities stood at $18.3 million in 2021, then dropped by 6.69% to $17.1 million in 2022, then decreased by 28.8% to $12.1 million in 2023, then fell by 13.79% to $10.5 million in 2024, then grew by 20.42% to $12.6 million in 2025.
  • Its Total Current Liabilities stands at $12.6 million for Q3 2025, versus $9.2 million for Q2 2025 and $9.8 million for Q1 2025.